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The strength of the T cell response against
a surrogate tumor antigen (TA) induced
by oncolytic vesicular stomatitis virus
(VSV) therapy does not correlate with
tumor control
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The last decade has seen the develop-
ment of numerous antitumor therapeutic
approaches. Concomitantly, the interest for
using oncolytic viruses (OV) against can-
cer has grown tremendously and a number
of promising candidates are now in pre-
clinical and clinical studies. Tumor regres-
sion in vivo following viral infection has
been shown to be a multifactorial process
(1). The reductionist view of viruses sim-
ply causing direct lysis of infected can-
cer cells has now been replaced by a view
including the complex interplay between
viruses and the tumor environment. The
important role of the immune response in
either limiting or enhancing OV therapy is
also now well recognized (2, 3). The pro-
totypic Rhabdoviridae VSV has generated
encouraging results in various experimen-
tal tumor models and is now used in a phase
I clinical trial in patients with liver cancer
(www.clinicaltrials.gov; #NCT01628640).
VSV possesses intrinsic oncolytic proper-
ties as it replicates more efficiently in type-I
interferon (IFN)-defective cells, a pathway
frequently impaired during tumorigenesis
(4). Cancer therapy using VSV has been
shown to generate a variety of immune
responses including tumor-specific CD8+
T cells that are induced following the
release of TA by infected cells (5). How-
ever, the tumor-specific immune response
generated following VSV treatment is usu-
ally weak and often only leads to tran-
sient tumor control. Experimental tumor
models expressing various surrogate non-
self-TA have been developed over the years
to more easily assess the magnitude and
quality of immune responses generated
against tumors. However, whether these
responses are always representative of phys-
iological antitumor immune responses is
unclear.
Recently, our group characterized vari-
ous VSV glycoprotein (G) mutants capa-
ble of interfering with host cell metab-
olism by inhibiting cellular transcription
and translation in a kinetic similar to WT
VSV as opposed to the prototypic matrix
(M) mutant (MM51R) that is slightly atten-
uated in vitro (6). Furthermore, VSV G
mutants proved to be more cytolytic for
B16 melanoma cells in vitro than the M
mutant. To analyze their oncolytic poten-
tial in vivo, we used an immunocompetent
mouse model implanted with B16 tumors
transfected with a DNA minigene encoding
the immunodominant CD8+ T cell epitope
of the lymphocytic choriomeningitis virus
(glycoprotein aa 33–41) (7) as a surro-
gate non-self-TA (B16gp33) (8). Mice were
injected subcutaneously into the flank with
B16gp33 cells and when tumors reached a
palpable size (day 7), animals were treated
intratumorally every second day with three
doses (days 7, 9, and 11) of WT VSV
or of the G or M mutants. Tetramer
and intracellular cytokine staining analy-
sis revealed that CD8+ T cells harvested
from mice treated with WT VSV or the G
mutants developed a polyfunctional gp33-
specific immune response. Surprisingly
however, the strength of the gp33-specific
immune response generated did not corre-
late with the ability of a particular strain
of VSV to slow down parental B16 growth
and improve mice survival. Treatment with
WT VSV was the poorest at controlling B16
tumor progression even though it induced
a strong CTL response against gp33. On
the other hand, MM51R was more efficient
than WT VSV at slowing down B16 growth
despite the fact that this virus induced
the lowest gp33-specific T cell response.
We therefore determined whether CD8+ T
cell responses directed against endogenous
self-TA were involved in limiting tumor
progression. CTL responses against self-
TA, such as TRP-1 and gp100, were barely
detectable ex vivo when analyzed sepa-
rately. However, adoptive transfer of puri-
fied CD8+ T cells harvested from MM51R-
treated B16gp33 melanoma-bearing mice
into naive mice provided better protec-
tion against parental B16 tumor implan-
tation compared to CTLs taken from WT
or G mutant-treated mice. These results
suggest that the M mutant, despite being
the weakest at inducing a T cell response
against the surrogate non-self-TA gp33,
induces the broadest antitumoral CTL
response.
B16 melanoma is a highly aggressive
tumor model in part because major his-
tocompatibility complex class I (MHC-I)
surface expression is very low on these
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FIGURE 1 | Induction of a functional tumor-specific immune response is
achieved through diverse mechanisms for different VSV strains:
proposed model. VSV is quickly cleared from tumor tissue by the rapid
induction of innate antiviral defense mechanisms and neutralizing antibodies.
Nonetheless, the proinflammatory milieu generated in response to infection
promotes leukocyte infiltration. Infection can result in tumor cell lysis either
directly as a result of virus replication or indirectly through the action of innate
immune cells generating a pool of tumor-associated antigens that may be
taken-up by antigen-presenting cells such as dendritic cells and lead to T
lymphocyte activation. Infection with WT VSV or glycoprotein (G) mutants
induces a strong CD8+ cytotoxic T lymphocyte (CTL) response against a
surrogate non-self antigen (gp33) correlating with their ability to limit tumor
growth (left panel). In contrast, the matrix mutant of VSV (MM51R), although
inefficient at inducing gp33-specific CTLs, is highly effective at slowing down
tumor progression, likely through its capacity to induce the upregulation of
MHC-I surface expression on cancer cells allowing for the induction of a
broader CTL response (right panel). CTLs, cytotoxic T lymphocytes; DC,
dendritic cells; MDSC, myeloid-derived suppressor cell; MHC-I, major
histocompatibility complex class I; NK, natural killer; VSV, vesicular stomatitis
virus.
cells. Strikingly, B16 infection with VSV M
mutant induced the upregulation of sur-
face MHC-I both in vitro and in vivo, a
phenomenon that was not observed for
WT VSV of the G mutants (8). The matrix
protein of VSV was previously shown to
alter trafficking of a molecule structurally
similar to MHC-I, namely CD1d (9, 10).
This leads to inhibition of antigen pre-
sentation to natural killer T (NKT) cells
(11). Thus, VSV matrix protein could
participate in the retention of MHC-
I molecules within infected cells while
the mutated protein in MM51R may lack
this ability. Thus, surface MHC-I upreg-
ulation following MM51R treatment likely
explains the significantly improved CD8+
T cell-dependent survival despite the
poor gp33-specific CTL response induced
by this mutant. This may subsequently
lead to presentation of a broader pool
of B16 TA proportionally reducing the
response against gp33 (see Figure 1 for
model).
In a recent study, Pedersen et al.
compared vaccine-induced CD8+ T cell
responses directed against self and non-
self-TA and showed that vaccination with
adenoviral vectors encoding endogenous
TA had little or no effect on the growth
of B16 melanomas whereas vaccination
with a similar vector construct express-
ing a surrogate non-self-TA induced effi-
cient tumor control (12). Although vacci-
nation against both self and non-self-TA
induced comparable CD8+ T cell responses
in terms of cell numbers and effector func-
tions, CTLs directed against self-TA were
of lower functional avidity. These results
are in agreement with our study and pro-
vide a potential mechanism explaining why
T cell responses against self and non-
self-TA are different and might not be
induced at proportional levels during OV
therapy.
Taken together, these results highlight
a considerable limitation of many exper-
imental systems used to assess antitu-
mor immunity and warrant caution when
extrapolating responses against surrogate
TA to the overall antitumoral immune
response. This may prove critical for the
development of novel or improved OV,
which may be biased by incorrectly esti-
mating immune response correlates using
such experimental systems. Therefore,
great efforts will need to be made to develop
improved methods for analyzing the anti-
tumoral immune response induced by OVs
against a broader array of TA in order
to better appreciate their full therapeutic
potential.
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